Evidence map›Paper›PMID 24486361›Full record

ArticleVaccine2014

Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen.

Celine A Hayden, Emily M Smith, Debra D Turner, Todd K Keener, Jeffrey C Wong, John H Walker, Ian R Tizard, Rafael Jimenez-Flores, John A Howard

Abstract read
In one paragraph

Article in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. PlantsFrontiers in plant science · 2022
    Review
  5. Review
  6. Review
  7. Article
  8. Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever.The Journal of infectious diseases · 2019
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Hepatitis B virus large surface protein: function and fame.Hepatobiliary surgery and nutrition · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Celine A HaydenApplied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA.
Emily M SmithApplied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA.
Debra D TurnerDepartment of Veterinary Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA.
Todd K KeenerApplied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA.
Jeffrey C WongHorticulture and Crop Science Department, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
John H WalkerDepartment of Statistics, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
Ian R TizardDepartment of Veterinary Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA.
Rafael Jimenez-FloresDairy Product Technology Center, California Polytechnic State University, San Luis Obispo, CA 93407, USA.
John A HowardApplied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA. Electronic address: jhoward@appliedbiotech.org.

Funding

An Orally Delivered Booster Vaccine Candidate for Hepatitis BR44AI068239 · NIAID · APPLIED BIOTECHNOLOGY INSTITUTE · PI HOWARD, JOHN A. · 2012 to 2014
$2.6M
NIAID NIH HHS 2R44AI068239-03A1NIAID NIH HHS R44 AI068239
6 · The paper itself

Abstract

The hepatitis B virus continues to be a major pathogen worldwide despite the availability of an effective parenteral vaccine for over 20 years. Orally-delivered subunit vaccines produced in maize may help to alleviate the disease burden by providing a low-cost, heat-stable alternative to the parenteral vaccine. Oral subunit vaccination has been an elusive goal due to the large amounts of antigen required to induce an immunologic response when administered through the digestive tract. Here we show that high levels of HBsAg were obtained in maize grain, the grain was formed into edible wafers, and wafers were fed to mice at a concentration of approximately 300 μg/g. When these wafers were made with supercritical fluid extraction (SFE)-treated maize material, robust IgG and IgA responses in sera were observed that were comparable to the injected commercial vaccine (Recombivax(®)). In addition, all mice administered SFE wafers showed high secretory IgA titers in fecal material whereas Recombivax(®) treated mice showed no detectable titer. Increased salivary IgA titers were also detected in SFE-fed mice but not in Recombivax(®) treated mice. Wafers made from hexane-treated or full fat maize material induced immunologic responses, but fecal titers were attenuated relative to those produced by SFE-treated wafers. These responses demonstrate the feasibility of using a two-dose oral vaccine booster in the absence of an adjuvant to induce immunologic responses in both sera and at mucosal surfaces, and highlight the potential limitations of using an exclusively parenteral dosing regime.

Indexed as

Immunity, MucosalAdministration, OralAnimalsChromatography, Supercritical FluidHepatitis AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesImmunoglobulin AImmunoglobulin A, SecretoryImmunoglobulin GMiceMice, Inbred BALB CPlants, Genetically ModifiedVaccines, SubunitVaccines, SyntheticZea maysHepatitis AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesImmunoglobulin AImmunoglobulin A, SecretoryImmunoglobulin GRecombivax HBVaccines, SubunitVaccines, SyntheticBioencapsulationHBsAgHepatitis BImmunogenicityMucosalOral vaccinePlant vaccineSupercritical fluid extraction

Identifiers

PMID24486361
PMCPMC3999707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.